Patent EP0115394A2 successfully refreshed from Google Patents.
← Back to Patent Explorer
EP0115394A2 Expired / Lapsed EP ⏱️ 0.0 years remaining

Phenothiazone derivatives and analogs

Assignee: Merck Frosst Canada and Co
•
Filing: 1984-01-16
•
Granted: —
•
Expires: 2004-01-16
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Phenothiazine compounds of formula where X is in the 1 or 3 position and is O, S or NR; R is H, C 1 -C 6 branched or linear alkyl, CN or phenyl; Y is 0, Se, S, SO, SO 2 or NR; and the broken line represents an optional double bond between the 1 and 2 or 2 and 3 position; each of R 1 , R 2 , R 3 and R 4 , independently of the others, is (1) hydrogen (2) C 1-6 alkyl, (3) C 2-6 alkenyl, (4) -(CH 2 ) n M where n is 0 or an integer from 1 to 6 and M is (a) OR 5 , (b) halogen, (c) CF 3 , (d) SR 5 where R 5 is H; alkoxyalkyl; acyloxyalkyl; C 1-6 alkyl; benzyl; phenyl or substituted phenyl where the substituents are C 1-3 alkyl, halogen, CN, CF 3 , COOR 6 , CH 2 COOR 6 , (CH 2 ) n NR 8 R 9 where n is 0, 1 or 2, C 1-3 alkoxy, OH, C 1-6 haloalkyl, -(CH 2 ) m COOR 6 , where m is 0 or an integer from 1 to 6 and R 6 is H, phenyl or C 1-6 alkyl; CN, formyl; perfluoroalkyl; or CH 2 -R 12 , where R 12 is C 1-5 alkyl, phenyl or dimethylamino; (e) phenyl or substituted phenyl as defined above for R 5 ; (f) COOR 6 ; (g) where R 14 is H, (CH 2 ) n COOR 6 where n is 0 or an integer from 1 to 4, C 1-6 alkyl, CF 3 , phenyl, or substituted phenyl as defined above for R 5 ; (h) tetrazole; (i) where R 7 is C 1-8 alkyl, benzyl or phenyl; (j) -NR 8 R 9 where R e and R 9 are independently selected from H, phenyl or substituted phenyl as defined above for R 5 , C 1 -C 4 alkyl or C 1 -C 4 alkylaminoalkyl, or are joined through the N to form a heterocycloalkyl of 5-8 ring atoms; (k) -NHSO 2 R 10 where R 10 is OH, C 1 -C 6 alkyl, C 1 -C 6 - alkoxy, phenyl or CF 3 ; (m) -SOR 11 where R 11 is C 1 -C 6 alkyl, phenyl or substituted phenyl as defined above for R 5 , (CH 2 ) m COOR 6 where m is 1 to 6, CN, formyl or C 1-4 perfluoroalkyl; (p) -SO 2 R 13 where R 13 is OH, H, C 1 -C 6 alkyl, phenyl or substituted phenyl as defined above for R 5 , (CH 2 ) m COOR 6 where m is 1 to 6, CN or C 1-4 perfluoroalkyl; (q) NO 2 ; (r) (s) (t) (u) -CN; or (v) NR 15 R 16 where R 15 and R 16 are such that HNR 15 R 16 is an essential amino acid; or any two of R 1 , R 2 , R 3 and R 4 are joined to form a fourth saturated or unsaturated C 5-6 ring, and T is H, halogen or CF 3 . are useful as inhibitors of mammalian leukotriene biosynthesis and therefore are useful therapeutic agents for treatng pain, skin conditions, allergic conditions, pulmonary conditions, asthma, cardiovascular disorders and inflammation. They are included in pharmaceutical compositions. Certain of the compounds are novel.

Inventors

  • 👤 Yvan Guindon
  • 👤 Rejean Fortin
  • 👤 Cheuk K. Lau
  • 👤 Joshua Rokach
  • 👤 Christiane Yoakim

Bibliographic Details

Application Number —
Jurisdiction EP
Data Source google_patents
Last Synchronized 2026-10-28 13:34
CPC Classifications
C; C07; C07D; C07D293/00; C07D293/10; A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/535; A61K31/54; C07C; C07C46/00; C07C46/02; C07C46/06; C07D241/00; C07D241/36; C07D241/38; C07D241/46; C07D265/00; C07D265/28; C07D265/34; C07D265/38; C07D279/00; C07D279/10; C07D279/14; C07D279/18; C07D279/34; C07D279/36

Claims Analysis

Total Claims: 29
Claim 1
Independent Claim 582 words
A pharmaceutical composition for inhibiting mammalian leukotriene biosynthesis or action containing an effective amount of a compound of the Formula I: wherein X is in the 1 or 3 position and is O, S or NR; R is H, C 1 -C 6 branched or linear alkyl, CN or phenyl; Y is O, Se, S, SO, S0 2 or NR; and the broken line represents an optional double bond between the 1 and 2 or 2 and 3 position; R 1 , R 2 , R 3 and R 4 are each independently selected from: (1) hydrogen, (2) alkyl having 1-6 carbon atoms, (3) alkenyl having 2-6 carbon atoms, (4) -(CH 2 ) n M wherein n is 0-6 and M is a) OR 5 , b) halogen, c) CF 3 , d) SR 5 wherein R 5 is H; lower alkoxyl-loweralkyl; lower acyloxy-loweralkyl; C 1 -C 6 alkyl; benzyl; phenyl or substituted phenyl wherein the substituents are C 1 -C 3 alkyl, halogen, CN, CF 3 , COOR 6 , CH 2 C OOR 6 , (CH 2 ) n NR 8 R 9 wherein n is 0 to 2, C 1 -C 3 alkoxy, O H , halo-C 1 -C 6 -alkyl; -(CH 2 ) m COOR 6 , wherein m is 0 to 6 and R 6 is H, phenyl or C 1 -C 6 alkyl; CN, formyl; perfluoroalkyl; or CH 2 -R 12 , wherein R 12 is C 1 -C 5 alkyl, phenyl or dimethylamino; e) phenyl or substituted phenyl as defined above for R 5 ; f ) COOR 6 ; g ) -R 14 wherein R 14 is H, (CH 2 ) n COOR 6 wherein n is 0 to 4, C 1 -C 6 alkyl, CF 3 , phenyl, or substituted phenyl as defined above for R 5 ; h) tetrazole: i) wherein R 7 is C 1 -C 6 alkyl benzyl or phenyl; j) -NR 8 R 9 wherein R 8 and R 9 are independently selected from H, phenyl or substituted phenyl as defined above for R 5 or C 1 -C 4 alkyl, C 1 -C 4 alkylaminoalkyl, or may be joined through the N to form a heterocycloalkyl of 5-8 ring atoms; k) -NHSO 2 R 10 wherein R 10 is O H, C 1 -C 6 alkyl, C 1 -C 6 -alkoxy, phenyl or CF 3 ; 1) m) -SOR 11 wherein R 11 is C 1 -C 6 alkyl, phenyl or substituted phenyl as defined above for R 5 , (CH 2 ) m COOR 6 wherein m is 1 to 6, CN, formyl or perfluoro- C l - C 4 alkyl; n ) -CONR 8 R 9 o) -SO 2 NR 8 R 9 ; p ) -SO 2 R 13 wherein R 13 is OH, H, C 1 -C 6 -alkyl, phenyl or substituted phenyl as defined above for R 5 , (CH 2 ) m COOR 6 wherein m is 1 to 6, CN or perfluoro-C 1 -C 4 alkyl; q ) NO 2 ; r) s) t) u) -CN ; v) NR 15 R 16 wherein R 15 and.R l6 are such that HNR 15 R 16 is an essential amino acid; Any two of R 1 , R 2 , R 3 and R 4 may be joined to form a fourth ring, which may be saturated or unsaturated, of five or six carbons and; T is H, halogen or CF 3 .
Claim 2
Dependent Claim 582 words
A pharmaceutical composition for inhibiting mammalian leukotriene biosynthesis or action containing an effective amount of a compound of the Formula I: wherein X is in the 1 or 3 position and is O, S or NR; R is H, C 1 -C 6 branched or linear alkyl, CN or phenyl; Y is O, Se, S, SO, S0 2 or NR; and the broken line represents an optional double bond between the 1 and 2 or 2 and 3 position; R 1 , R 2 , R 3 and R 4 are each independently selected from: (1) hydrogen, (2) alkyl having 1-6 carbon atoms, (3) alkenyl having 2-6 carbon atoms, (4) -(CH 2 ) n M wherein n is 0-6 and M is a) OR 5 , b) halogen, c) CF 3 , d) SR 5 wherein R 5 is H; lower alkoxyl-loweralkyl; lower acyloxy-loweralkyl; C 1 -C 6 alkyl; benzyl; phenyl or substituted phenyl wherein the substituents are C 1 -C 3 alkyl, halogen, CN, CF 3 , COOR 6 , CH 2 C OOR 6 , (CH 2 ) n NR 8 R 9 wherein n is 0 to 2, C 1 -C 3 alkoxy, O H , halo-C 1 -C 6 -alkyl; -(CH 2 ) m COOR 6 , wherein m is 0 to 6 and R 6 is H, phenyl or C 1 -C 6 alkyl; CN, formyl; perfluoroalkyl; or CH 2 -R 12 , wherein R 12 is C 1 -C 5 alkyl, phenyl or dimethylamino; e) phenyl or substituted phenyl as defined above for R 5 ; f ) COOR 6 ; g ) -R 14 wherein R 14 is H, (CH 2 ) n COOR 6 wherein n is 0 to 4, C 1 -C 6 alkyl, CF 3 , phenyl, or substituted phenyl as defined above for R 5 ; h) tetrazole: i) wherein R 7 is C 1 -C 6 alkyl benzyl or phenyl; j) -NR 8 R 9 wherein R 8 and R 9 are independently selected from H, phenyl or substituted phenyl as defined above for R 5 or C 1 -C 4 alkyl, C 1 -C 4 alkylaminoalkyl, or may be joined through the N to form a heterocycloalkyl of 5-8 ring atoms; k) -NHSO 2 R 10 wherein R 10 is O H, C 1 -C 6 alkyl, C 1 -C 6 -alkoxy, phenyl or CF 3 ; 1) m) -SOR 11 wherein R 11 is C 1 -C 6 alkyl, phenyl or substituted phenyl as defined above for R 5 , (CH 2 ) m COOR 6 wherein m is 1 to 6, CN, formyl or perfluoro- C l - C 4 alkyl; n ) -CONR 8 R 9 o) -SO 2 NR 8 R 9 ; p ) -SO 2 R 13 wherein R 13 is OH, H, C 1 -C 6 -alkyl, phenyl or substituted phenyl as defined above for R 5 , (CH 2 ) m COOR 6 wherein m is 1 to 6, CN or perfluoro-C 1 -C 4 alkyl; q ) NO 2 ; r) s) t) u) -CN ; v) NR 15 R 16 wherein R 15 and.R l6 are such that HNR 15 R 16 is an essential amino acid; Any two of R 1 , R 2 , R 3 and R 4 may be joined to form a fourth ring, which may be saturated or unsaturated, of five or six carbons and; T is H, halogen or CF 3 .
Claim 3
Dependent Claim 11 words
The composition of Claim 1 wherein X is in the 1-position.
Claim 4
Dependent Claim 11 words
The composition of Claim 2 wherein X is O or NR.
Claim 5
Dependent Claim 31 words
The composition of Claim 3 wherein Y is S, SO, SO 2 , NR or O and in the structural unit (CH 2 ) n M, n is 0 or 1.
Claim 6
Dependent Claim 13 words
The composition of Claim 4 wherein X is O and Y is S.
Claim 7
Dependent Claim 11 words
The composition of Claim 1 wherein X is in the 3-position.
Claim 8
Dependent Claim 11 words
The composition of Claim 6 wherein X is 0 or NR.
Claim 9
Dependent Claim 30 words
The composition of Claim 7 wherein Y is S, SO, SO 2 NR or 0 and in the structural unit (CH 2 ) n M, n is 0 or 1.
Claim 10
Dependent Claim 11 words
The composition of Claim 7 wherein Y is S or 0.
Claim 11
Dependent Claim 13 words
The composition of Claim 8 wherein X is 0 and Y is S.
Claim 12
Dependent Claim 15 words
The composition of Claim 2 wherein the Formula I compound is selected from the following:
Claim 13
Dependent Claim 15 words
The composition of Claim 8 wherein the Formula I compound is selected from the following:
Claim 14
Dependent Claim 15 words
The composition of Claim 8 wherein the Formula I compound is selected from the following:
Claim 15
Dependent Claim 22 words
The composition of Claim 8 wherein the Formula I compound is selected fran a compound of Formula II: wherein the substituents are:
Claim 16
Dependent Claim 46 words
A composition as claimed in Claim 1, for use in one or more of the following treatments: (1) inhibiting mammalian leukotriene biosynthesis or action, (2) treating pulmonary conditions, (3), treating inflammation, (4) treating allergies, (5) treating pain, (6) treating cardiovascular conditions and (7) treating skin conditions.
Claim 17
Dependent Claim 20 words
A composition as claimed in Claim 2, for use in one or more of the treatments defined in Claim 15.
Claim 18
Dependent Claim 20 words
A composition as claimed in Claim 6, for use in one or more of the treatments defined in Claim 15.
Claim 19
Dependent Claim 20 words
A composition as claimed in Claim 10, for use in one or more of the treatments defined in Claim 15.
Claim 20
Dependent Claim 20 words
A composition as claimed in Claim 11, for use in one or more of the treatments defined in Claim 15.
Claim 21
Dependent Claim 20 words
The compounds of the Formula: wherein the substituents are: and R is H or C 2 to C 4 alkyl.
Claim 22
Dependent Claim 20 words
The compounds of the Formula: wherein the substituents are: and R is H or C 2 to C 4 alkyl.
Claim 23
Dependent Claim 21 words
The compounds of the Formula: wherein the substituents are: and wherein R is H or C 1 to C 4 alkyl.
Claim 24
Dependent Claim 21 words
The compounds of the Formula: wherein the substituents are: and wherein R is H or C 1 to C 4 alkyl.
Claim 25
Dependent Claim 9 words
The compounds of the formula: wherein the substituents are:
Claim 26
Dependent Claim 9 words
The compounds of the formula: wherein the substituents are:
Claim 27
Dependent Claim 4 words
The compounds: 2-S-glutathionyl-3H-phenothiazin-3-one; 4-chloro-2-S-glutathionyl-phenothiazin-3-one.
Claim 28
Dependent Claim 4 words
The compounds: 2-S-glutathionyl-3H-phenothiazin-3-one; 4-chloro-2-S-glutathionyl-phenothiazin-3-one.
Claim 29
Dependent Claim 55 words
The composition of Claim 1 additionally containing a second active ingredient selected from the group consisting of non-steriodal anti- inflamnatory agents; peripheral analgesic agents; cyclooxygenase inhibitors; leukotriene antagonists; antihistaminic agents; prostaglandin antagonists; and thromboxane antagonists, wherein the weight ratio of said Formula I compound to said second active ingredient ranges from about 10:1 to 1:10.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Maintenance schedule is calculated for granted US utility patents.

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag